Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components

6 Months Ended

Jun. 30, 2019

NOTE 6 — BALANCE SHEET COMPONENTS

Accrued liabilities were comprised of the following (in thousands):

	June 30,		December 31,
	2019		2018
Accrued liabilities:
General and administrative	$	1,059	$	297
Clinical trial related costs		1,355		598
Non-clinical research and manufacturing operations		3,140		2,644
Payroll related		1,510		1,787
Other accrued expenses		56		31
Total accrued liabilities	$	7,120	$	5,357

Deferred revenue was comprised of the following:

	June 30,		December 31,
	2019		2018
Deferred revenue:
Research and development agreements	$	16,225	$	28,901

Other assets include $3.0 million of restricted cash as of June 30, 2019.